- Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
- KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases
- Kazia announces presentation of new data at AACR Annual Meeting
Key statistics
As of last trade, Kazia Therapeutics Ltd (KZIA:NAQ) traded at 0.2598, 39.23% above the 52 week low of 0.1866 set on Mar 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.266 |
---|---|
High | 0.270 |
Low | 0.2407 |
Bid | 0.2502 |
Offer | 0.2598 |
Previous close | 0.266 |
Average volume | 118.78k |
---|---|
Shares outstanding | 13.18m |
Free float | 777.07k |
P/E (TTM) | -- |
Market cap | 6.85m USD |
EPS (TTM) | -0.8257 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 19:44 BST.
More ▼